We were delighted to speak to Laure Gossec (Sorbonne Université and Pitié-Salpétrière Hospital, Paris, France) about the 48-week results of the BE ACTIVE phase 2b study of bimekizumab in psoriatic arthritis (Clinical Trial Identifier: NCT02969525). The abstract ‘Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity‘ (ABSTRACT NUMBER: 0356) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- Could you tell us a little about bimekizumab and its mechanism of action? (0:15)
- Why are patient-reported outcomes (PROs) important and what are the most useful PROs in psoriatic arthritis? (0:37)
- Could you tell us a little about the BE ACTIVE study? (1:25)
- What were the major findings of the BE ACTIVE study? (2:09)
- How well did the PROs correlate with disease activity, and what are the implications of these findings for clinical practice? (3:07)
Disclosures: Research grants: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi; consulting fees: AbbVie, Amgen, BMS, Biogen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, UCB.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR Convergence 2020 (Virtual).
Share this Video
Related Videos In Psoriatic Arthritis
Maarten Boers, EULAR 2021: Findings from the ULTIMATE Clinical Trial
It was great to talk with Prof. Maarten Boers (VU University Medical Center, Amsterdam, The Netherlands) to discuss the responsiveness and high discriminative validity of GLOESS and clinical outcomes of synovitis in PsA patients treated with secukinumab from the ULTIMATE Trial. The abstract ‘Responsiveness of Ultrasound Synovitis and Clinical Outcomes in Psoriatic Arthritis Treated with […]
Xenofon Baraliakos, EULAR 2021: Findings from the MAXIMISE Study
It was a pleasure to meet with Prof. Xenofon Baraliakos (Ruhr-University Bochum, Herne, Germany) to talk around his presentation on ‘Secukinumab in patients with psoriatic arthritis and axial manifestations: Predictors of response from the double-blind, randomised, phase 3b MAXIMISE trial.‘ (POS0930), which was presented at the European Congress of Rheumatology 2021, 2-5 June 2021. Questions […]
Peter Taylor, EULAR 2021: Highlights from the Congress
We had the pleasure to meet with our Editor-in-Chief, Professor Peter C Taylor (University of Oxford, Oxford, UK) who gave us some of the key highlights from this year’s European Congress of Rheumatology meeting, 2-5 June 2021. Questions What were the highlights of this year’s EULAR meeting? (0:11) Disclosures: Peter C Taylor reports receiving: Research grants […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!